Development of the quantitative determination method for a new caries-preventive compound
Keywords:pharmaceutical analysis, quantitative determination, validation of the analytical method, cetylpyridinium hexafluorosilicate, caries-preventive agent
Fluorides are the most important treatment and preventive additive in the composition of any form; they prevent development of caries by increasing the resistance of enamel, as well as production of acids by bacteria of dental plaque. At the Odessa National Medical University the work on searching for fluorine-containing compounds in a series of quaternary bases and their subsequent use in dentistry is conducted. The pharmacological studies have shown that “onium” hexafluorosilicates have a higher caries-preventive effectiveness compared to sodium fluoride. Cetylpyridinium hexafluorosilicate has been found to be the most active in the dose of 15 mg/kg when used in the form of oral applications of the gel; its mechanism of action is in activation of alkaline phosphatase and lysozyme of the pulp of the teeth. Development of reliable methods for identification and quantitative determination is a prerequisite for further use of this compound in medical practice. The aim of this work was to develop the method for quantitative determination cetylpyridinium hexafluorosilicate. For further use of the method proposed for analysis of the compound under research its validation characteristics have been studied. According to the results of the research conducted it has been found that the method for quantitative determination of cetylpyridinium hexafluorosilicate in the substance corresponds to the following parameters: accuracy, precision, linearity (= 0.50 ≤ max=0.53, d = 0.17 ≤ max d = 0.32, a=0.80 max a=1.60, r=1.0000 min r=0.9993).
Державна Фармакопея України : в 3 т. / Державне підприємство «Український науковий фармакопейний центр якості лікарських засобів». – 2-е вид. – Харків : Державне підприємство «Український науковий фармакопейний центр якості лікарських засобів», 2015. – Т. 1. – 1128 с.
British Pharmacopoeia [Електронний ресурс]. / The British Pharmacopoeia Secretariat. – London, 2009. – Vol. II. – Режим доступу: https://www.vek-com.ru/78022.html.
European Pharmacopoeia 6th ed. – Strasbourg: European Directorate for the Quality of Medicines, 2008 – Vol. 2. – 3308 p.
Gelmboldt V. O., Anisimov V. Yu., Bevz N. Yu., Georgiyants V. A. // Der Pharma Chemica. – 2016. – Vol. 8, № 1. – P. 169-173.
Gelmboldt V. O., Ganin Ed. V., Fonari M. S. and oth. // J. Fluorine Chem. – 2009. – Vol. 130. – P. 428-433.
Gelmboldt V. O., Prodan O. V., Anisimov V. Yu. // American Journal of PharmTech Research. – 2014. – Vol. 4, № 6. – P. 513-521.
Lepsky V. V., Anisimov V. Yu., Lepsky V. V. // Journal of Education, Health and sport. – 2015. – Vol. 5, № 11. – P. 289-299.
Levitsky A. P., Gorokhivskiy V. N., Selivanskaya I. A. // Aktual'nye problemy transportnoy meditsiny. – 2014. – Vol. 3, № 37. – P. 136-139.
Copyright (c) 2016 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).